Arovella Therapeutics Share Price and Company Fundamentals
Last traded: Today at 3:09 AM
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Key Metrics
PE ratio
-
PB ratio
4.56
Dividend yield
-
Beta
0.09
Market cap
$88.24M
Enterprise value
$67.94M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.arovella.com |
| Mailing address | Corporate One 84 Hotham Road Preston VIC 3072 Australia |
| Phone / Fax | 61 3 9863 6472 / |
Dividends
More: Arovella Therapeutics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Arovella Therapeutics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.ALA dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of May 2026, following are the company executives and directors listed on Arovella Therapeutics.
| Name | Title | Age | Total Pay |
|---|
Profitability and management effectiveness
Profit margin
-246.95%
Operating margin
-71.50%
Return on assets
-32.25%
Return on equity
-52.05%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Arovella Therapeutics is 88.24M and its enterprise value is 67.94M. The enterprise value to revenue ratio of ALA is 21.17. The enterprise value to EBITDA ratio of ALA is -8.12.
The ALA's stocks Beta value is 0.09 making it 91% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Arovella Therapeutics (ALA)
Arovella Therapeutics (ASX:ALA) Frequently Asked Questions
1. What is Arovella Therapeutics's Stock Symbol?
Arovella Therapeutics trades on ASX under the ticker symbol "ALA".
2. What is Arovella Therapeutics's stock price today?
One share of ALA stock can currently be purchased for approximately $0.073.
3. How can I contact Arovella Therapeutics?
Arovella Therapeutics's mailing address is Corporate One 84 Hotham Road Preston VIC 3072 Australia. The company can be reached via phone at 61 3 9863 6472.
4. What is Arovella Therapeutics's official website?
The official website of Arovella Therapeutics is https://www.arovella.com.